

ERRATUM

# Imeglimin, a novel, first in-class, blood glucose-lowering agent: a systematic review and meta-analysis of clinical evidence

THOMAS SJ CRABTREE, RALPH A DEFRONZO, ROBERT EJ RYDER, CLIFFORD J BAILEY

*Br J Diabetes* 2020;**20**:28-31 <https://doi.org/10.15277/bjd.2020.247>

In the article listed above, there was an error in Figure 2. Please find below the corrected figure.

**Figure 2.** Forest plot showing meta-analysis of imeglimin versus placebo for (a) HbA<sub>1c</sub> (%) and (b) fasting plasma glucose levels (mmol/L) using a random-effect model. Risk of bias assessment is also included

